Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
Avelumab + Paclitaxel/ Ramucirumab as second line treatment in gastro-esophageal
adenocarcinoma following first-line therapy with platinum and fluoropyrimidine doublet with
or without anthracycline, docetaxel or trastuzumab